Endonovo Therapeutics (ENDV) Common Equity (2016 - 2023)
Endonovo Therapeutics has reported Common Equity over the past 13 years, most recently at -$23.0 million for Q3 2023.
- Quarterly results put Common Equity at -$23.0 million for Q3 2023, down 17.11% from a year ago — trailing twelve months through Sep 2023 was -$23.0 million (down 17.11% YoY), and the annual figure for FY2022 was -$32.2 million, down 104.0%.
- Common Equity for Q3 2023 was -$23.0 million at Endonovo Therapeutics, down from -$22.4 million in the prior quarter.
- Over the last five years, Common Equity for ENDV hit a ceiling of -$11.1 million in Q1 2020 and a floor of -$32.2 million in Q4 2022.
- Median Common Equity over the past 5 years was -$17.0 million (2021), compared with a mean of -$18.0 million.
- Biggest five-year swings in Common Equity: grew 29.9% in 2020 and later tumbled 104.0% in 2022.
- Endonovo Therapeutics' Common Equity stood at -$20.5 million in 2019, then grew by 29.9% to -$14.4 million in 2020, then decreased by 9.74% to -$15.8 million in 2021, then tumbled by 104.0% to -$32.2 million in 2022, then grew by 28.65% to -$23.0 million in 2023.
- The last three reported values for Common Equity were -$23.0 million (Q3 2023), -$22.4 million (Q2 2023), and -$24.4 million (Q1 2023) per Business Quant data.